Breaking Finance News

DBV Technologies SA – ADR (NASDAQ:DBVT) has been upgraded to Sell in a report by BidaskClub earlier today.

Having a price of $34.94, DBV Technologies SA – ADR (NASDAQ:DBVT) traded 0.14% higher on the day. The last stock close price is down 17.12% from the two hundred day average, compared with the S&P 500 Index which has increased 0.04% over the same time. The company has recorded a 50-day moving average of $44.12 and a 200-day moving average of $37.59. Trade Volume was down over the average, with 57,967 shares of DBVT changing hands under the typical 144,988

BidaskClub has upgraded DBV Technologies SA – ADR (NASDAQ:DBVT) to Sell in a statement released on Wednesday June 21, 2017.

Recent Performance Chart

DBV Technologies SA - ADR (NASDAQ:DBVT)

DBV Technologies SA – ADR has with a one year low of $31.87 and a one year high of $46.33 and has a market capitalization of $0.

A total of 7 analysts have released a report on DBV Technologies SA – ADR. Four analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $53.50.

Brief Synopsis On DBV Technologies SA – ADR (NASDAQ:DBVT)

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.